Tridek-One
Évry
About Tridek-One
Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and give them a better life.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $19.4M
- Last round: Series Unknown (Sep 2022)
- Website: tridekone.com
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/tridek-one-92857 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.